Le Lézard
Classified in: Health
Subject: PDT

Takara Bio Announces Launch of Beta Cell Differentiation Service

MOUNTAIN VIEW, Calif., May 17, 2018 /PRNewswire/ -- The Takara Bio Group, the leading provider of human stem cell differentiation services globally, has launched the Cellartis® Directed Differentiation to Beta Cells Service for the delivery of high-quality, custom human induced pluripotent stem cell (hiPSC)-derived beta cells for diabetes research and metabolic disease modeling.

Takara Bio, Inc., Contributing to the health of humankind through the development of revolutionary biotechnologies such as gene therapy.

The gold standard in this field involves the use of primary islets of Langerhans, which are difficult and costly to obtain. Islets containing insulin-secreting beta cells come from donors with different genetic backgrounds, confounding results by adding variability to cellular models and assays. The new differentiation service complements an existing suite of stem cell services and provides a reliable and plentiful source of mature beta cells from customer-specified hiPSCs, enabling beta cell functional studies, diabetes modeling, and compound screening for insulin secretion and regulation.

Catharina Brandsten, Director R&D at Takara Bio Europe AB, said, "Compared with human primary pancreatic islet beta cells, iPS-derived beta cells provide better access to cells and reduced batch-to-batch variability, providing reproducible and biologically relevant data. Our standardized method mimics embryonic development to manufacture large quantities of cryopreserved beta cells that secrete insulin and C-peptide, making the cells an excellent research tool for disease modeling and drug discovery."

About Takara Bio
The Takara Bio Group of companies is committed to improving the human condition through biotechnology. It is led by Takara Bio Inc. which represents the biomedical business interests of its parent company, Takara Holdings Inc. The Takara Bio companies support the life science market through the Takara, Clontech, and Cellartis brands, with the Cellartis brand focusing on stem cell-derived products and services for drug discovery, disease modeling, and applications within regenerative medicine. Learn more about Takara Bio at takara-bio.com (Japanese) and takarabio.com (English).


SOURCE Takara Bio Group

These press releases may also interest you

at 11:28
UNICEF Goodwill Ambassador Priyanka Chopra has called for more support for vulnerable Rohingya refugee children and women following a four-day trip to refugee camps and informal settlements in Cox's Bazar, Bangladesh. "After seeing the distressing...

at 11:24
Breast cancer survivors are not getting the recommended level of screening, post-surgery, according to a newly-published study in JNCCN ? Journal of the National Comprehensive Cancer Network. The study was led by Kathryn Ruddy, MD, MPH, Director of...

at 11:15
The "Intranasal Drug Delivery - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. Annual estimates and forecasts are provided for the period 2016 through 2024. Also, a five-year historic analysis is...

at 11:07
The International Society for Magnetic Resonance in Medicine (ISMRM) and the European Society of Magnetic Resonance in Medicine and Biology (ESMRMB) invite attendees at their joint annual meeting (www.ismrm.org) to attend the Presidential Lecture on...

at 11:00
AGC Biologics, a global leader in clinical and commercial manufacturing of therapeutic proteins, announced today that it will supply bulk drug substance for the launch of Portola Pharmaceuticals' Andexxa® [coagulation factor Xa (recombinant),...

at 11:00
Maine Magazine announced today that they are a proud sponsor of the Trek Across Maine presented by the American Lung Association.    The Trek Across Maine is a three-day, 180-mile route cycling tour from the mountains of Sunday River Ski Resort to...

News published on 17 may 2018 at 08:00 and distributed by: